



The 25th JFCR-ISCC

New Antitumor Agents under Development in the US, Europe and Japan

2021

December 8 (Wed) 12:00 - 18:30 - 9 (Thu) 8:00 - 15:00

Miraikan 2-3-6, Aomi, Koto-ku, Tokyo, Japan
National Museum of Emerging Science and Innovation



SPECIAL LECTURE

William G. Kaelin, Jr., M.D.
Nobel Prize Laureate in Physiology or Medicine 2019

Session 1 13:00 -

New frontiers in CAR-mediated cancer immunotherapy

Bob Valamehr Fate Therapeutics Inc.
iPSC-derived, multiplexed engineered CAR NK and T cell products targeting hematological and solid tumors

Shin Kaneko CiRA, Kyoto Univ.
Induced pluripotent stem cell-derived immune cells for CAR-based cancer immunotherapy

Yuki Kagoya Aichi Cancer Ctr.
Future perspectives of CAR-T cell therapy for cancer

Poster Flash Talks 14:50 -

Session 2 16:00 -

New targets and strategies for maximizing the therapeutic outcomes

Ryohei Katayama JFCR
Potential therapeutic strategies for overcoming intrinsic and acquired resistance in ALK+NSCLC

Martijn P. Lolkema Erasmus Univ. Medical Ctr.
Large scale genomic analyses of metastatic cancer from biomarker discovery to patient selection for drug treatment

Tomohiro Yamaguchi MSD K.K.
Development of a first-in-class HIF-2 α inhibitor, MK-6482

Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)"



Meet-the-Expert Session 17:50 -

Discovery of innovative new cancer drugs and chemical probes for probing cancer biology and target validation

Paul Workman Inst. Cancer Res. UK

Session 3 8:00 -

The next stage of cancer immune and antibody therapies

Mika Kamata-Sakurai Chugai Pharmaceutical, Co., Ltd.
A novel tumor selective anti-CD137 agonist antibody activated by elevated extracellular ATP in tumor microenvironment

Seema Gorla Astellas
An overview of the enfortumab vedotin development program

Lillian Siu Princess Margaret Cancer Ctr.
Applications of ctDNA beyond genotyping - e.g., determination of molecular residual disease, predicting IO response

Yosuke Togashi Okayama Univ.
Cancer immunogenomics for the next stage of precision medicine

Session 4 10:30 -

Blocking KRAS driver mutants and its acquired resistance

Ryan Corcoran MGH Cancer Ctr.
Clinical acquired resistance to KRASG12C inhibition

Hiromichi Ebi Aichi Cancer Ctr.
Targeting mutant KRAS based on its dependency in cancer cell survival

James G. Christensen Mirati Therapeutics
Adagrasib/MRTX849 and a KRAS G12D inhibitor, MRTX1133

Special Lecture 12:35 -

(Re)emerging principles of cancer therapy

William G. Kaelin, Jr. Dana-Farber Cancer Institute

<http://iscc.umin.jp/>

Contact : Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, jfcr-iscc@ml.jfcr.or.jp

The 25th JFCR-ISCC is supported by following companies: MSD K.K., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Zenyaku Kogyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and AbbVie Inc.

DEC. 8, WED

DEC. 9, THU